Lilly Wows ADA Crowd With Obesity Data Across Three-Drug Incretin Portfolio

Weight Loss Of Up To 24.2% With ‘Triple G’ Retatrutide

Black and white scale on wood floor
Lilly presented data at ADA on three obesity drugs • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D